Clinical Trials Logo

Clinical Trial Summary

The purpose of the study is to assess the gastrointestinal tolerability of EC-MPS compared to MMF in maintenance transplant patients on a calcineurin inhibitor regimen, who require MMF dose reductions of 25% or more due to GI complications. The tested hypothesis is that the EC-MPS treatment is superior to the MMF therapy in terms of tolerability and that patients on the EC-MPS formulation will be able to tolerate higher doses compared to those on MMF.


Clinical Trial Description

The use of mycophenolate mofetil (MMF) in combination with a calcineurin inhibitor (CNI: tacrolimus or cyclosporine) has been shown to improve graft survival in renal, cardiac and liver transplantation patients. However, its use has been associated with significant side effects, including gastrointestinal complications, causing dose reductions, interruption or termination of the therapy. An alternate formulation: enteric coated mycophenolate sodium (EC-MPS) was designed to alleviate the severity of upper gastrointestinal side effects. Several trials detailed in the protocol suggest a benefit in GI related health following conversion from MMF to EC-MPS, however we believe that robust data are lacking. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00611494
Study type Interventional
Source University Health Network, Toronto
Contact
Status Recruiting
Phase Phase 4
Start date January 2008
Completion date December 2009

See also
  Status Clinical Trial Phase
Recruiting NCT00987103 - Pharmacokinetic Study to Rectal and Sublingual Administration of Tacrolimus in Future Kidney Transplant Patients Phase 1
Completed NCT03699839 - Reducing the Burden of Influenza After Solid-Organ Transplantation Phase 2/Phase 3
Completed NCT01633424 - The "Stanford Integrated Psychosocial Assessment for Transplant" (SIPAT)
Completed NCT01254955 - Antibody Production Following H1N1 Influenza Vaccination in Organ Transplant Patients N/A
Completed NCT00948883 - Study of Cancers After Solid Organs Transplants N/A
Recruiting NCT02314949 - Leuven Tolerogenic Protocol for Intestinal Transplantation N/A
Recruiting NCT01283295 - Immune Monitoring and Assay Development in Organ Transplant Recipients
Not yet recruiting NCT03861962 - Re-evaluation of Donor-specific Anti-HLA Alloantibodies Immunoassay After Organ Transplantation, From Antigen Level to Epitope Level
Completed NCT01123187 - Islet Cell Transplantation in Patients With Type I Diabetes With Previous Kidney Transplantation N/A
Completed NCT00213304 - The Safety of Oka Varicella in Children Prior to Solid Organ Transplantation Phase 3
Completed NCT01515072 - Remote Ischemic Preconditioning in Neurological Death Organ Donors N/A
Completed NCT00904579 - Cancer Risk in Organ Transplant Recipients and End-Stage Renal Disease
Recruiting NCT04687865 - Constitution of a Biobank for Studies Related to Organ Transplantation (Lyon Centaure Biocollection)
Completed NCT02852902 - Impact of Specific Antimicrobials and MIC Values on the Outcome of Bloodstream Infections Due to ESBL- or Carbapenemase-producing Enterobacterales in Solid Organ Transplantation: an Observational Multinational Study.
Completed NCT05685888 - Effect of Ursodeoxycholic Acid on Preventing Covid-19 Infection in Patients With Organ Transplantation
Recruiting NCT00792064 - Systematic Evaluation of Predictors of Quality of Life in the Long-term After Solid Organ Transplantation N/A
Completed NCT00734396 - Mesenchymal Stem Cells and Subclinical Rejection Phase 1/Phase 2
Completed NCT00286871 - Randomized Controlled Trial in Liver Transplant Recipients Treated in Steroid Sparing Regimen Phase 1
Recruiting NCT03997253 - Optimizing Long-term Survival in Organ Transplantation: From Physiopathology to Optimized Patient Management N/A
Recruiting NCT01256931 - Antibody Levels Against 2009 Influenza A H1N1 One Year After Vaccination With Pandemrix and 2010 Fluarix Booster in Organ Transplant Recipients. N/A